Mesenchymal stem/stromal cell quality control: validation of mixed lymphocyte reaction assay using flow cytometry according to ICH Q2(R1)

[1] Kozlowska U(2019)Similarities and differences between mesenchymal stem/progenitor cells derived from various human tissues World J Stem Cells 11 347-374

[2] Krawczenko A(2018)Mesenchymal stem cell-based immunomodulation: properties and clinical application Stem Cells Int 2018 3057624-797

[3] Futoma K(2017)Regulatory perspective on in vitro potency assays for human mesenchymal stromal cells used in immunotherapy Cytother 19 784-159

[4] Jurek T(2015)International Society for Cellular Therapy perspective on immune functional assays for mesenchymal stromal cells as potency release criterion for advanced phase clinical trials Cytother 18 151-11

[5] Rorat M(2015)A robust potency assay highlights significant donor variation of human mesenchymal stem/progenitor cell immune modulatory capacity and extended radio-resistance Stem Cell Res Ther 6 1-11

[6] Patrzalek D(2017)An in vitro potency assay for monitoring the immunomodulatory potential of stromal cell-derived extracellular vesicles Int J Mol Sci 18 1-317

[7] Wang M(2006)Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement Cytotherapy. 8 315-273

[8] Yuan Q(2018)Enhanced immunosuppressive properties of human mesenchymal stem cells primed by interferon-γ EBioMedicine 28 261-E2607

[9] Xie L(2017)Morphological features of IFN-γ–stimulated mesenchymal stromal cells predict overall immunosuppressive capacity Proc Natl Acad Sci 114 E2598-8

[10] de Wolf C(2015)Comparing the immunomodulatory properties of bone marrow, adipose tissue, and birth-associated tissue mesenchymal stromal cells Front Immunol 6 1-136

[1] Kozlowska U(2019)Similarities and differences between mesenchymal stem/progenitor cells derived from various human tissues World J Stem Cells 11 347-374

[2] Krawczenko A(2018)Mesenchymal stem cell-based immunomodulation: properties and clinical application Stem Cells Int 2018 3057624-797

[3] Futoma K(2017)Regulatory perspective on in vitro potency assays for human mesenchymal stromal cells used in immunotherapy Cytother 19 784-159

[4] Jurek T(2015)International Society for Cellular Therapy perspective on immune functional assays for mesenchymal stromal cells as potency release criterion for advanced phase clinical trials Cytother 18 151-11

[5] Rorat M(2015)A robust potency assay highlights significant donor variation of human mesenchymal stem/progenitor cell immune modulatory capacity and extended radio-resistance Stem Cell Res Ther 6 1-11

[6] Patrzalek D(2017)An in vitro potency assay for monitoring the immunomodulatory potential of stromal cell-derived extracellular vesicles Int J Mol Sci 18 1-317

[7] Wang M(2006)Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement Cytotherapy. 8 315-273

[8] Yuan Q(2018)Enhanced immunosuppressive properties of human mesenchymal stem cells primed by interferon-γ EBioMedicine 28 261-E2607

[9] Xie L(2017)Morphological features of IFN-γ–stimulated mesenchymal stromal cells predict overall immunosuppressive capacity Proc Natl Acad Sci 114 E2598-8

[10] de Wolf C(2015)Comparing the immunomodulatory properties of bone marrow, adipose tissue, and birth-associated tissue mesenchymal stromal cells Front Immunol 6 1-136